PT Saptausaha Gemilangindah Tbk (SAGE)
Jul 31, 2025 - SAGE was delisted (reason: acquired by SUPN)
8.68
-0.02 (-0.23%)
Inactive · Last trade price on Jul 30, 2025

Sage Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
9726---
Upgrade
Market Cap Growth
28.19%-73.19%----
Upgrade
Enterprise Value
11827---
Upgrade
Last Close Price
0.000.000.00---
Upgrade
PE Ratio
-1455.3784.18---
Upgrade
PS Ratio
16.046.6618.29---
Upgrade
PB Ratio
0.530.391.40---
Upgrade
P/TBV Ratio
0.530.391.40---
Upgrade
EV/Sales Ratio
18.607.8218.93---
Upgrade
EV/EBITDA Ratio
-124.8071.77---
Upgrade
EV/EBIT Ratio
-168.4172.97---
Upgrade
Debt / Equity Ratio
0.080.080.050.070.090.07
Upgrade
Debt / EBITDA Ratio
-21.262.420.691.71-
Upgrade
Asset Turnover
0.030.050.080.130.100.02
Upgrade
Inventory Turnover
0.070.120.210.390.300.06
Upgrade
Quick Ratio
0.190.460.950.040.040.02
Upgrade
Current Ratio
4.825.154.720.330.360.32
Upgrade
Return on Equity (ROE)
-1.09%0.03%2.30%9.62%4.33%-5.67%
Upgrade
Return on Assets (ROA)
-0.49%0.15%1.21%3.02%1.42%-1.02%
Upgrade
Return on Capital (ROIC)
-0.51%0.16%1.62%6.30%3.15%-1.67%
Upgrade
Return on Capital Employed (ROCE)
-0.30%1.90%9.60%4.80%-
Upgrade
Earnings Yield
-2.07%0.07%1.19%---
Upgrade
Buyback Yield / Dilution
9.37%0.00%-25.06%--180.45%-281.98%
Upgrade
Updated Apr 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q